AKT1 and obesity disorder: In diet‐induced obesity mouse model, supplemented thymoquinone at the rate of 20 mg/kg BW per day prevented diabetic phenotype via lowering the glucose concentration, fasting insulins, serum cholesterol, triglycerides, and inflammatory markers resistin and MCP‐1, improving the glucose tolerance and insulin sensitivity, and enhancing the phosphorylated Akt level, whereas it phosphorylated SIRT‐1 in skeletal muscle and phosphorylated SIRT‐1 and AMPKα in liver (Shpetim et al., 2017).